JPI-547, a novel dual inhibitor of PARP1/2 and tankyrase is more effective than first-generation PARP inhibitors in preclinical BRCA1/2-mutated cancer modelsMin Sil Kang, Yong Wha Moon|British Journal of Cancer|2026Cited by 0